Global Veterinary API Market Size, Share & Industry Trends Analysis Report By Route of Administration, By API Type, By Synthesis Type, By Animal Type, By Regional Outlook and Forecast, 2023 - 2030

Global Veterinary API Market Size, Share & Industry Trends Analysis Report By Route of Administration, By API Type, By Synthesis Type, By Animal Type, By Regional Outlook and Forecast, 2023 - 2030


The Global Veterinary API Market size is expected to reach $12.9 billion by 2030, rising at a market growth of 6.4% CAGR during the forecast period.

The market expansion can be attributed to factors such as the increasing demand for meat and meat products, the growing concern for animal health and welfare, and technological advancements in animal husbandry. Therefore, the Hormones segment generated $566.6 million revenue in the market in 2022. Animal hormones are substances produced by an animal's body that regulate numerous vital physiological processes, including growth, development, reproduction, and metabolism. Increased understanding among farm and pet owners regarding the accessibility of veterinarians and animal healthcare products is the primary reason for the significant increase in animal medicalization rates in developing nations. The increased number of veterinary visits increased the demand for diagnostic tests and treatment options, increasing the demand for anti-infectives, anti-microbial, antiparasitics, vaccines, etc. Some of the factors impacting the market are increase in understanding of animal health and welfare, increasing prevalence of transboundary and zoonotic diseases, and difficulties in large-molecular-weight API synthesis.

The public's cognizance of animal health and welfare has increased significantly. People are becoming increasingly aware of the significance of providing appropriate care and consideration to animals, including domesticated companions, livestock, and untamed animals. Many organizations are examining the factors that have contributed to the growing awareness of animal health and welfare and the consequences for the veterinary industry and society. Local and international animal welfare organizations have been essential in raising understanding about animal health and welfare. These organizations campaign for the rights and well-being of animals, encourage responsible ownership of pets, and emphasize the significance of humane animal treatment. Due to their potential to cause significant injury to both animals and humans, transboundary and zoonotic diseases are currently a developing concern worldwide. These diseases, like avian influenza, rabies, and African swine fever, threaten public health, animal welfare, and international trade. Consequently, the use of veterinary active pharmaceutical ingredients (APIs) to fight against the spread of these diseases has increased. The availability of adequate and high-quality veterinary active pharmaceutical ingredients is crucial for supporting these initiatives, enabling international cooperation, and mitigating the detrimental effects of such ailments on public health and international trade.

However, the synthesis of large molecule APIs, like proteins and peptides, for veterinary applications presents unique challenges. These difficulties stem from the complexity of large molecules and the particular requirements for their production. Synthesis of large molecule APIs can be time-consuming and expensive. The complexity of the synthesis procedure, the need for specialized apparatus and reagents, and the possibility of low yields or purification difficulties can all contribute to increased expenses. It is necessary to optimize expression systems, such as genetic engineering, improvement of culture conditions, and purification methods, to produce enough large molecule APIs.

Furthermore, the argument that the COVID-19 pandemic decreased the need for animal care is accurate. In most veterinary hospitals, clinics, and other facilities, foot traffic was restricted due to the global outbreak, infection control measures, and state-wide lockdowns. Consequently, most key actors operated at a deficient level or need to be more competent. Lower output, as well as capacity in veterinary pharmaceutical production, might result in product unavailability and disrupted supply chains, which had a negative impact on market growth.

API Type Outlook

Based on API type, the market is categorized into parasiticides, vaccines, antimicrobials, anti-inflammatories, hormones, and others. In 2022, the parasiticides segment of the market recorded the highest revenue share. Increasing R&D spending on veterinary API production and rising parasitic infections in companion and livestock animals are expected to contribute to market expansion over the forecast period. Due to accelerated urbanization and increasing disposable income, pet ownership is rising in these nations. In these countries, more pet owners are willing to spend more on their pets' care, which supports the segment's demand.

Route of Administration Outlook

Based on route of administration, the market is segmented into oral, injectable, topical, and other segments. Injectables are anticipated to have a significant market revenue share in 2022. The segment's expansion can be attributed to the prevalence of chronic diseases in animals, which has increased the demand for vaccines. In addition, increasing livestock populations and animal husbandry and commercializing animal products are projected to increase demand for vaccines, thereby driving segment expansion. Vaccinations against rabies, equine influenza virus, and foot-and-mouth disease are the most frequently administered animal vaccines, which inhibit the transmission of infectious pathogens by reproducing naturally acquired immunity.

Synthesis Type Outlook

Based on synthesis type, the market is segmented by type of synthesis into chemical-based API, biological API, and highly potent API. In 2022, the biological API segment captured a significant market revenue share. This results from the widespread commercial acceptance of these products and increased research on biological veterinary medications. A number of pharmaceutical companies and contract API manufacturers provide biological APIs for the development of specific therapeutic medications for chronic veterinary diseases such as cancer.

Animal Type Outlook

On the basis of animal type, the market is segmented by animal type into companion animals and livestock animals. In 2022, the companion animals segment of the market attained a substantial revenue share. This is due to the rise in pet ownership, the increasing prevalence/incidence of various diseases, the rising cost of pet healthcare, and the large number of companies offering pet pharmaceutical products. Pet owners around the globe are increasingly willing to pay for veterinary medications, such as antibiotics, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), and parasiticides, among others. Such factors greatly contribute to market growth.

Regional Outlook

Regionally, the market is analyzed in North America, Europe, Asia Pacific, and LAMEA. North America dominated the market in 2022 by generating the highest revenue share. Significant localized prominence of major animal healthcare companies, beneficial reimbursement programs, an elevated incidence of zoonotic diseases, and expanding R&D in veterinary healthcare all contribute to this substantial share. Zoonoses (zoonotic diseases) are a significant problem in North America because they pose an additional hazard to public health, given that animals are frequently the source of infectious diseases. The high prevalence of zoonotic diseases is a further factor leading to segment growth.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Zoetis, Inc., Elanco Animal Health, Inc., Merck & Co., Inc., Virbac, Vetoquinol SA (Soparfin SCA), Sequent Scientific Limited, Phibro Animal Health Corporation, Febbrica Italina Sintetici S.P.A. (Nine Trees Group S.p.A) and Excel Industries Limited.

Strategies Deployed in Veterinary API Market

Sep-2022: Boehringer Ingelheim Animal Health introduced Fencovis, a new calf sour vaccine with a prevention claim, offering unresistant immunity to calves through the cows’ maternal colostrum. With Fencovis, a prevention claims against E. coli F5 and bovine rotavirus, Boehringer Ingelheim Animal Health offers a holistic lean approach to cattle farming through its support and training services.

Sep-2022: Zoetis, Inc. took over Jurox, a provider of livestock and Companion Animal products. Through this acquisition, Jurox brings Zoetis a spectrum of key products primed for larger global expansion, a valuable animal health suite, consisting of Alfaxan, an anesthetic product for companion animals.

Aug-2022: Merck & Co., Inc. announced expanded production of its facility based in Carlow. The expansion would play a key role in making sure that they continue to sustain future supply to meet medical requirements.

Jul-2022: Virbac launched TENOTRYL (enrofloxacin), an injectable solution for use in swine and cattle. This launch aims to serve veterinarians and customers, swine, and cattle producers, and also a suite of new alternatives to improve the health of livestock and finally their profitability.

Jul-2022: Zoetis completed the acquisition of Fish Vet Group from Benchmark Holdings PLC, a leading bioagtech company. Following this acquisition, Fish Vet Group would be a strategic addition to Zoetis' Pharmaq business which develops and sells fish vaccines and provides services in diagnostics and vaccination for aquaculture.

Jan-2022: Zoetis Inc. got FDA approval for Solensia, a once-monthly injection administered in the veterinary clinic. The approved injection aims to control the pain of osteoarthritis (OA) in cats, helping enhance their comfort, mobility, and overall well-being.

May-2021: Boehringer Ingelheim India unveiled poultry vaccine VAXXITEK HVT+IBD, an advanced recombinant vaccine. The launched vaccine is a single-shot vaccine, making sure life-long protection for all kinds of production chickens, namely broiler, layer, and breeder.

May-2021: Zoetis released the porcine circovirus vaccine, the only vaccine that consists of two porcine circovirus type two genotypes. The vaccine offers wider coverage against PCV2 and protection against two of the main pathogens in the worldwide pig industry.

Jan-2021: Boehringer Ingelheim partnered with PetMedix, a company engaged in creating treatment solutions for pets. Following this partnership, both companies would aim to advance novel and changeable companion animal antibody therapeutics utilizing PetMedix's properietary Ky9™ platform. Additionally, PetMedix would undertake discovery activities against a number of key targets, and Boehringer Ingelheim would work to develop and bring these therapies to market.

Aug-2019: Elanco Animal Health Inc. took over Prevtec Microbia Inc., a biotechnology startup with expertise in the development of vaccines that help prevent bacteria diseases in food animals. Prevtec offers the line of Coliprotec vaccine, a product designed to protect pigs. Following this acquisition, Elanco would be an exclusive distributor for Coliprotec across Europe and Canada. Moreover, this acquisition brings Prevtec's research and development programs to Elanco's portfolio.

Jun-2019: Elanco Animal Health completed the acquisition of Aratana Therapeutics, a pet therapeutics company engaged in the development and sales of advanced therapeutics for dogs and cats, and developer of Galliprnat, a first-of-its-kind canine NSAID for osteoarthritis. This acquisition enables Elanco to capture the complete value of the growing product Galliprant and introduce two new products - Entyce, the only FDA-approved veterinary therapeutic, and Nocita, a long-acting local anaesthetic, in Elanco's portfolio.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration
  • Oral
  • Injectable
  • Topical
  • Others
By API Type
  • Parasiticides
  • Anti-inflammatory
  • Antimicrobials
  • Vaccines
  • Hormones
  • Others
By Synthesis Type
  • Chemical based API
  • Biological API
  • Highly potent API
By Animal Type
  • Livestock Animals
  • Companion Animals
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Boehringer Ingelheim International GmbH
  • Zoetis, Inc.
  • Elanco Animal Health, Inc.
  • Merck & Co., Inc.
  • Virbac
  • Vetoquinol SA (Soparfin SCA)
  • Sequent Scientific Limited
  • Phibro Animal Health Corporation
  • Febbrica Italina Sintetici S.P.A. (Nine Trees Group S.p.A)
  • Excel Industries Limited
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Veterinary API Market, by Route of Administration
1.4.2 Global Veterinary API Market, by API Type
1.4.3 Global Veterinary API Market, by Synthesis Type
1.4.4 Global Veterinary API Market, by Animal Type
1.4.5 Global Veterinary API Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Force Analysis
Chapter 4. Strategies Deployed in Veterinary API Market
Chapter 5. Global Veterinary API Market by Route of Administration
5.1 Global Oral Market by Region
5.2 Global Injectable Market by Region
5.3 Global Topical Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Veterinary API Market by API Type
6.1 Global Parasiticides Market by Region
6.2 Global Anti-inflammatory Market by Region
6.3 Global Antimicrobials Market by Region
6.4 Global Vaccines Market by Region
6.5 Global Hormones Market by Region
6.6 Global Others Market by Region
Chapter 7. Global Veterinary API Market by Synthesis Type
7.1 Global Chemical based API Market by Region
7.2 Global Biological API Market by Region
7.3 Global Highly potent API Market by Region
Chapter 8. Global Veterinary API Market by Animal Type
8.1 Global Livestock Animals Market by Region
8.2 Global Companion Animals Market by Region
Chapter 9. Global Veterinary API Market by Region
9.1 North America Veterinary API Market
9.1.1 North America Veterinary API Market by Route of Administration
9.1.1.1 North America Oral Market by Country
9.1.1.2 North America Injectable Market by Country
9.1.1.3 North America Topical Market by Country
9.1.1.4 North America Others Market by Country
9.1.2 North America Veterinary API Market by API Type
9.1.2.1 North America Parasiticides Market by Country
9.1.2.2 North America Anti-inflammatory Market by Country
9.1.2.3 North America Antimicrobials Market by Country
9.1.2.4 North America Vaccines Market by Country
9.1.2.5 North America Hormones Market by Country
9.1.2.6 North America Others Market by Country
9.1.3 North America Veterinary API Market by Synthesis Type
9.1.3.1 North America Chemical based API Market by Country
9.1.3.2 North America Biological API Market by Country
9.1.3.3 North America Highly potent API Market by Country
9.1.4 North America Veterinary API Market by Animal Type
9.1.4.1 North America Livestock Animals Market by Country
9.1.4.2 North America Companion Animals Market by Country
9.1.5 North America Veterinary API Market by Country
9.1.5.1 US Veterinary API Market
9.1.5.1.1 US Veterinary API Market by Route of Administration
9.1.5.1.2 US Veterinary API Market by API Type
9.1.5.1.3 US Veterinary API Market by Synthesis Type
9.1.5.1.4 US Veterinary API Market by Animal Type
9.1.5.2 Canada Veterinary API Market
9.1.5.2.1 Canada Veterinary API Market by Route of Administration
9.1.5.2.2 Canada Veterinary API Market by API Type
9.1.5.2.3 Canada Veterinary API Market by Synthesis Type
9.1.5.2.4 Canada Veterinary API Market by Animal Type
9.1.5.3 Mexico Veterinary API Market
9.1.5.3.1 Mexico Veterinary API Market by Route of Administration
9.1.5.3.2 Mexico Veterinary API Market by API Type
9.1.5.3.3 Mexico Veterinary API Market by Synthesis Type
9.1.5.3.4 Mexico Veterinary API Market by Animal Type
9.1.5.4 Rest of North America Veterinary API Market
9.1.5.4.1 Rest of North America Veterinary API Market by Route of Administration
9.1.5.4.2 Rest of North America Veterinary API Market by API Type
9.1.5.4.3 Rest of North America Veterinary API Market by Synthesis Type
9.1.5.4.4 Rest of North America Veterinary API Market by Animal Type
9.2 Europe Veterinary API Market
9.2.1 Europe Veterinary API Market by Route of Administration
9.2.1.1 Europe Oral Market by Country
9.2.1.2 Europe Injectable Market by Country
9.2.1.3 Europe Topical Market by Country
9.2.1.4 Europe Others Market by Country
9.2.2 Europe Veterinary API Market by API Type
9.2.2.1 Europe Parasiticides Market by Country
9.2.2.2 Europe Anti-inflammatory Market by Country
9.2.2.3 Europe Antimicrobials Market by Country
9.2.2.4 Europe Vaccines Market by Country
9.2.2.5 Europe Hormones Market by Country
9.2.2.6 Europe Others Market by Country
9.2.3 Europe Veterinary API Market by Synthesis Type
9.2.3.1 Europe Chemical based API Market by Country
9.2.3.2 Europe Biological API Market by Country
9.2.3.3 Europe Highly potent API Market by Country
9.2.4 Europe Veterinary API Market by Animal Type
9.2.4.1 Europe Livestock Animals Market by Country
9.2.4.2 Europe Companion Animals Market by Country
9.2.5 Europe Veterinary API Market by Country
9.2.5.1 Germany Veterinary API Market
9.2.5.1.1 Germany Veterinary API Market by Route of Administration
9.2.5.1.2 Germany Veterinary API Market by API Type
9.2.5.1.3 Germany Veterinary API Market by Synthesis Type
9.2.5.1.4 Germany Veterinary API Market by Animal Type
9.2.5.2 UK Veterinary API Market
9.2.5.2.1 UK Veterinary API Market by Route of Administration
9.2.5.2.2 UK Veterinary API Market by API Type
9.2.5.2.3 UK Veterinary API Market by Synthesis Type
9.2.5.2.4 UK Veterinary API Market by Animal Type
9.2.5.3 France Veterinary API Market
9.2.5.3.1 France Veterinary API Market by Route of Administration
9.2.5.3.2 France Veterinary API Market by API Type
9.2.5.3.3 France Veterinary API Market by Synthesis Type
9.2.5.3.4 France Veterinary API Market by Animal Type
9.2.5.4 Russia Veterinary API Market
9.2.5.4.1 Russia Veterinary API Market by Route of Administration
9.2.5.4.2 Russia Veterinary API Market by API Type
9.2.5.4.3 Russia Veterinary API Market by Synthesis Type
9.2.5.4.4 Russia Veterinary API Market by Animal Type
9.2.5.5 Spain Veterinary API Market
9.2.5.5.1 Spain Veterinary API Market by Route of Administration
9.2.5.5.2 Spain Veterinary API Market by API Type
9.2.5.5.3 Spain Veterinary API Market by Synthesis Type
9.2.5.5.4 Spain Veterinary API Market by Animal Type
9.2.5.6 Italy Veterinary API Market
9.2.5.6.1 Italy Veterinary API Market by Route of Administration
9.2.5.6.2 Italy Veterinary API Market by API Type
9.2.5.6.3 Italy Veterinary API Market by Synthesis Type
9.2.5.6.4 Italy Veterinary API Market by Animal Type
9.2.5.7 Rest of Europe Veterinary API Market
9.2.5.7.1 Rest of Europe Veterinary API Market by Route of Administration
9.2.5.7.2 Rest of Europe Veterinary API Market by API Type
9.2.5.7.3 Rest of Europe Veterinary API Market by Synthesis Type
9.2.5.7.4 Rest of Europe Veterinary API Market by Animal Type
9.3 Asia Pacific Veterinary API Market
9.3.1 Asia Pacific Veterinary API Market by Route of Administration
9.3.1.1 Asia Pacific Oral Market by Country
9.3.1.2 Asia Pacific Injectable Market by Country
9.3.1.3 Asia Pacific Topical Market by Country
9.3.1.4 Asia Pacific Others Market by Country
9.3.2 Asia Pacific Veterinary API Market by API Type
9.3.2.1 Asia Pacific Parasiticides Market by Country
9.3.2.2 Asia Pacific Anti-inflammatory Market by Country
9.3.2.3 Asia Pacific Antimicrobials Market by Country
9.3.2.4 Asia Pacific Vaccines Market by Country
9.3.2.5 Asia Pacific Hormones Market by Country
9.3.2.6 Asia Pacific Others Market by Country
9.3.3 Asia Pacific Veterinary API Market by Synthesis Type
9.3.3.1 Asia Pacific Chemical based API Market by Country
9.3.3.2 Asia Pacific Biological API Market by Country
9.3.3.3 Asia Pacific Highly potent API Market by Country
9.3.4 Asia Pacific Veterinary API Market by Animal Type
9.3.4.1 Asia Pacific Livestock Animals Market by Country
9.3.4.2 Asia Pacific Companion Animals Market by Country
9.3.5 Asia Pacific Veterinary API Market by Country
9.3.5.1 China Veterinary API Market
9.3.5.1.1 China Veterinary API Market by Route of Administration
9.3.5.1.2 China Veterinary API Market by API Type
9.3.5.1.3 China Veterinary API Market by Synthesis Type
9.3.5.1.4 China Veterinary API Market by Animal Type
9.3.5.2 Japan Veterinary API Market
9.3.5.2.1 Japan Veterinary API Market by Route of Administration
9.3.5.2.2 Japan Veterinary API Market by API Type
9.3.5.2.3 Japan Veterinary API Market by Synthesis Type
9.3.5.2.4 Japan Veterinary API Market by Animal Type
9.3.5.3 India Veterinary API Market
9.3.5.3.1 India Veterinary API Market by Route of Administration
9.3.5.3.2 India Veterinary API Market by API Type
9.3.5.3.3 India Veterinary API Market by Synthesis Type
9.3.5.3.4 India Veterinary API Market by Animal Type
9.3.5.4 South Korea Veterinary API Market
9.3.5.4.1 South Korea Veterinary API Market by Route of Administration
9.3.5.4.2 South Korea Veterinary API Market by API Type
9.3.5.4.3 South Korea Veterinary API Market by Synthesis Type
9.3.5.4.4 South Korea Veterinary API Market by Animal Type
9.3.5.5 Singapore Veterinary API Market
9.3.5.5.1 Singapore Veterinary API Market by Route of Administration
9.3.5.5.2 Singapore Veterinary API Market by API Type
9.3.5.5.3 Singapore Veterinary API Market by Synthesis Type
9.3.5.5.4 Singapore Veterinary API Market by Animal Type
9.3.5.6 Malaysia Veterinary API Market
9.3.5.6.1 Malaysia Veterinary API Market by Route of Administration
9.3.5.6.2 Malaysia Veterinary API Market by API Type
9.3.5.6.3 Malaysia Veterinary API Market by Synthesis Type
9.3.5.6.4 Malaysia Veterinary API Market by Animal Type
9.3.5.7 Rest of Asia Pacific Veterinary API Market
9.3.5.7.1 Rest of Asia Pacific Veterinary API Market by Route of Administration
9.3.5.7.2 Rest of Asia Pacific Veterinary API Market by API Type
9.3.5.7.3 Rest of Asia Pacific Veterinary API Market by Synthesis Type
9.3.5.7.4 Rest of Asia Pacific Veterinary API Market by Animal Type
9.4 LAMEA Veterinary API Market
9.4.1 LAMEA Veterinary API Market by Route of Administration
9.4.1.1 LAMEA Oral Market by Country
9.4.1.2 LAMEA Injectable Market by Country
9.4.1.3 LAMEA Topical Market by Country
9.4.1.4 LAMEA Others Market by Country
9.4.2 LAMEA Veterinary API Market by API Type
9.4.2.1 LAMEA Parasiticides Market by Country
9.4.2.2 LAMEA Anti-inflammatory Market by Country
9.4.2.3 LAMEA Antimicrobials Market by Country
9.4.2.4 LAMEA Vaccines Market by Country
9.4.2.5 LAMEA Hormones Market by Country
9.4.2.6 LAMEA Others Market by Country
9.4.3 LAMEA Veterinary API Market by Synthesis Type
9.4.3.1 LAMEA Chemical based API Market by Country
9.4.3.2 LAMEA Biological API Market by Country
9.4.3.3 LAMEA Highly potent API Market by Country
9.4.4 LAMEA Veterinary API Market by Animal Type
9.4.4.1 LAMEA Livestock Animals Market by Country
9.4.4.2 LAMEA Companion Animals Market by Country
9.4.5 LAMEA Veterinary API Market by Country
9.4.5.1 Brazil Veterinary API Market
9.4.5.1.1 Brazil Veterinary API Market by Route of Administration
9.4.5.1.2 Brazil Veterinary API Market by API Type
9.4.5.1.3 Brazil Veterinary API Market by Synthesis Type
9.4.5.1.4 Brazil Veterinary API Market by Animal Type
9.4.5.2 Argentina Veterinary API Market
9.4.5.2.1 Argentina Veterinary API Market by Route of Administration
9.4.5.2.2 Argentina Veterinary API Market by API Type
9.4.5.2.3 Argentina Veterinary API Market by Synthesis Type
9.4.5.2.4 Argentina Veterinary API Market by Animal Type
9.4.5.3 UAE Veterinary API Market
9.4.5.3.1 UAE Veterinary API Market by Route of Administration
9.4.5.3.2 UAE Veterinary API Market by API Type
9.4.5.3.3 UAE Veterinary API Market by Synthesis Type
9.4.5.3.4 UAE Veterinary API Market by Animal Type
9.4.5.4 Saudi Arabia Veterinary API Market
9.4.5.4.1 Saudi Arabia Veterinary API Market by Route of Administration
9.4.5.4.2 Saudi Arabia Veterinary API Market by API Type
9.4.5.4.3 Saudi Arabia Veterinary API Market by Synthesis Type
9.4.5.4.4 Saudi Arabia Veterinary API Market by Animal Type
9.4.5.5 South Africa Veterinary API Market
9.4.5.5.1 South Africa Veterinary API Market by Route of Administration
9.4.5.5.2 South Africa Veterinary API Market by API Type
9.4.5.5.3 South Africa Veterinary API Market by Synthesis Type
9.4.5.5.4 South Africa Veterinary API Market by Animal Type
9.4.5.6 Nigeria Veterinary API Market
9.4.5.6.1 Nigeria Veterinary API Market by Route of Administration
9.4.5.6.2 Nigeria Veterinary API Market by API Type
9.4.5.6.3 Nigeria Veterinary API Market by Synthesis Type
9.4.5.6.4 Nigeria Veterinary API Market by Animal Type
9.4.5.7 Rest of LAMEA Veterinary API Market
9.4.5.7.1 Rest of LAMEA Veterinary API Market by Route of Administration
9.4.5.7.2 Rest of LAMEA Veterinary API Market by API Type
9.4.5.7.3 Rest of LAMEA Veterinary API Market by Synthesis Type
9.4.5.7.4 Rest of LAMEA Veterinary API Market by Animal Type
Chapter 10. Company Profiles
10.1 Boehringer Ingelheim International Gmbh
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Regional & Segmental Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Product Launches and Product Expansions:
10.1.5.2 Partnerships, Collaborations and Agreements:
10.1.6 SWOT Analysis
10.2 Zoetis, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Product Launches and Product Expansions:
10.2.5.2 Approvals and Trials:
10.2.5.3 Acquisition and Mergers:
10.2.6 SWOT Analysis
10.3 Elanco Animal Health, Inc.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Acquisition and Mergers:
10.3.6 SWOT Analysis
10.4 Merck & Co., Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expenses
10.4.5 Recent strategies and developments:
10.4.5.1 Geographical Expansions:
10.4.6 SWOT Analysis
10.5 Virbac
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Recent strategies and developments:
10.5.4.1 Product Launches and Product Expansions:
10.5.5 SWOT Analysis
10.6 Vetoquinol SA (Soparfin SCA)
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 SWOT Analysis
10.7 Sequent Scientific Limited
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 SWOT Analysis
10.8 Phibro Animal Health Corporation
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental and Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 SWOT Analysis
10.9 Febbrica Italina Sintetici S.P.A. (Nine Trees Group S.p.A)
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Regional Analysis
10.10. Excel Industries Limited
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental Analysis
10.10.4 SWOT Analysis
Chapter 11. Winning Imperatives for Veterinary API Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings